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Abstract
Background: Colon cancer is the second leading cause of cancer deaths in the western world. If
detected early, colorectal cancer is one of the most treatable forms of cancer. Unfortunately, very
few people are screened. N-myristoyltransferase (NMT) catalyzes myristoylation of various
proteins including oncoproteins. We have demonstrated earlier the alteration of NMT activity
during the progression of colorectal cancer and established NMT as a putative therapeutic target
for cancer.
Methods: Peripheral blood samples and bone marrow were collected from the colon cancer
patients and azoxymethane induced colonic tumor rats and their controls respectively. NMT
activity and expression was determined as reported earlier. Immunohistochemical studies were
carried out using standard procedures.
Results: In this study we demonstrate for the first time altered expression and localization of NMT
in the peripheral blood and bone marrow in colon cancer patients. Immunohistochemical analysis
revealed weak to negative staining for NMT in peripheral blood mononuclear cells (PBMC) of
controls, whereas strong positivity was observed in PBMC colon cancer patients. In addition, we
observed that NMT was localized mostly in the nuclei of the bone marrow (BM) mononuclear cells
of the colon cancer patients, whereas NMT remained cytoplasmic in the control bone marrow
specimens.
Conclusion: The strikingly different NMT expression offers the basis of a potential adjunct
investigative tool for screening or diagnosis of patients at risk for or suspected of having colon
cancer. Furthermore, altered localization of NMT in BM of tumor bearing hosts may serve as an
added investigative tool for the diagnostic purpose.
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Background
Recently, understanding the lipid modification of pro-
teins has gathered much attention. Protein N-myristoyla-
tion is one such lipid modification which involves the
covalent attachment of myristate (a 14 carbon saturated
fatty acid) to N-terminal glycine of a number of mamma-
lian, viral and fungal proteins [1]. N-myristoylation
renders proper function and intracellular trafficking of
proteins [2]. Many proteins involved in a wide variety of a
signal cascade, cellular transformation and oncogenesis
are myristoylated of which most important are several
tyrosine kinases such as pp60src, pp60yes, pp56lck, pp59fyn/
syn and c-Abl [3]. Myristoylation of proteins is catalyzed by
ubiquitously distributed eukaryotic enzyme N-myristoyl-
transferase (NMT) which is a member of GNAT super-
family of proteins [1-4]. NMT is an emerging therapeutic
and drug target [5,6] in various diseases. We have demon-
strated earlier the alteration of NMT activity during the
progression of colorectal cancer and established NMT as a
putative therapeutic target for cancer [7,8].
Colorectal cancer is highly curable if diagnosed early. The
primary prognostic approach to identify the differences
among the patients with early disease is the Tumor-Node-
Metastasis (TNM) system [9]. However, the survival out-
come varies among patient with similar pathological dis-
ease stage. There have been increasing demands to
identify the molecular markers of more aggressive colorec-
tal cancer in order to tailor patient therapy or to identify
the disease well in advance.
At present there are several putative biological markers
that play important roles in the pathogenesis, prolifera-
tion and invasion of colonic tumors. Examples include
epidermal growth factor receptor (EGFR), c-MET, β-cat-
enin and p53 [10]. However, a limitation of assessing the
expression of these markers or measuring NMT expression
and activity for prognostic/diagnostic purposes is that an
invasive biopsy must be performed to obtain tumor tissue
for protein analysis [8]. Therefore, we have been working
towards the detection of NMT in blood samples from
colorectal tumor bearing rat and cancer patients.
The result of the present study demonstrates for the first
time a simple prognostic/diagnostic tool for colorectal
cancer without involving surgery or biopsy. Moreover,
this putative marker for colorectal cancer in peripheral
blood is not associated with inflammatory response due
to the growth of the tumor as is the case for some other
markers of colorectal cancer [7].
Material and methods
Source of chemicals and biochemicals were described ear-
lier [6]. Peptide substrate based on the N-terminal ends of
cAMP-dependent protein kinase A (GNAAAKKRR) was
synthesized by the Alberta Peptide Institute, Canada.
Monoclonal antibodies were purchased from BD Bio-
sciences (Missisuaga, Canada). Polyclonal antibodies was
raised against purified human NMT in New Zealand white
rabbits and the specificity of this antibody has been
described previously [8].
Blood sample collection
Peripheral blood samples were collected from the colon
cancer patients (n = 8) and controls (n = 5) following
informed consent according to the guidelines of Univer-
sity of Saskatchewan. Blood smears were prepared for
immunohistochemical studies.
Azoxymethane-induced colonic tumors in rats
All procedures for animal experimentation were carried
out in accordance with guidelines of the Canadian Coun-
cil of Animal Care. Twenty Sprague-Dawley rats (weigh-
ing, Males: 250.8 ± 15.5; Female: 168.1 ± 9.02) were
obtained from Charles River Canada (St. Constant, Can-
ada). Rats were acclimatized for one week and randomly
allocated to treatment or control groups. Twelve rats (six
each of male and female) were given eight weekly subcu-
taneous injections of azoxymetane (10 mg/kg of body
weight) in saline. Eight control rats (four each of male and
female) were given eight weekly injections of saline only.
Animals were given rat chow and rat water ad libitum and
housed two per cage. Temperature, humidity and light
were controlled at 22°C, 50% and 12/12 hours (light/
dark) respectively. Animals were killed after 30 weeks by
CO2 asphyxiation. Peripheral blood was drawn from tail
and blood smears were made on a slide for immunohisto-
chemical studies. Blood from the main artery was col-
lected in vacutainer tubes containing EDTA for the
separation of mononuclear cells. The colons were
removed followed by flushing of ice-cold saline to remove
contents. Further colons were slit longitudinally, and
open flat on ice cold surface to count for size and number
of tumors.
Separation of peripheral blood mononuclear cells (PBMC)
Peripheral blood samples were used immediately for the
separation of mononuclear cells. PBMC were isolated
using Ficoll-Paque according to standard procedures. The
isolated PBMC were then resuspended in RPMI medium
and cell counts and viability determined. Further, PBMC
were lysed in RIPA buffer containing 1 mM PMSF, 10 mM
DTT and 1% of protease inhibitor cocktail.
Isolation of bone marrow
Bone marrow (BM) was obtained from the femurs of rats.
BM was obtained from the femoral shafts by flushing it
with PBS. Bone marrow was homogenized in RIPA buffer
as above. For immunohistochemical studies BM was fixed
in 10% formaldehyde and, following dehydration inJournal of Translational Medicine 2007, 5:58 http://www.translational-medicine.com/content/5/1/58
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ascending concentrations of ethanol and xylene, were
embedded in paraffin. Five μm thick sections were pre-
pared from archival blocks and placed on glass slides.
Bone marrow sections were used from three patients with
colon cancer and three controls with no history of any
kind of cancer. Bone marrow cells (BMC) were obtained
from the femurs of rats. BMC were agitated gently to pre-
pare a single cell suspension and were washed subse-
quently thrice in PBS. BMC were then incubated for 24 h
in a humidified air and 5% CO2 at 37°C. After washing
the cells remained adhered to the plastic culture plates
were bone marrow macrophages. Cells were lysed in RIPA
buffer as above and were subjected to Western analysis
and NMT assay.
Immunohistochemistry
Labeled streptavidin-avidin technique was used to local-
ize the primary antibodies after microwave antigen
retrieval. The primary antibodies used in this study were:
CD3 (polyclonal, 1:80 dilution, Neomarkers, Fairmont,
CA), CD20 (monoclonal, 1:20 dilution, Dako, Missis-
sauga, ON), and NMT (polyclonal, 1:50 dilution). Immu-
nohistochemical staining results were evaluated in a semi-
quantitative manner as follows: number of mononuclear
cells positive: none; rare- 10%; 10–30%, 30–50%, >50%.
Staining intensity was evaluated as being absent, weak,
moderate or strong.
N-Myristoyltransferase assay
[3H]myristoyl-CoA was synthesized and N-Myristoyl-
transferase activity was assayed as described previously
[6]. The assay mixture contained 40 mM Tris-HCl, pH7.4,
0.5 mM EGTA, 0.45 mM 2-mercaptoethanol, 1% Triton X-
100, peptide substrate (500 μM) and NMT in a total vol-
ume of 25 μL. The transferase reaction was initiated by the
addition of freshly generated [3H]myristoyl-CoA and was
incubated at 30°C for 30 min. One unit of NMT activity
was expressed as 1 pmol of myristoyl peptide formed per
min.
Western blot analysis
SDS-PAGE was carried using standard procedures and
Western blot analysis was performed as described previ-
ously [6] and probed with monoclonal antibody against
NMT-1 (1:250, dilution in blocking buffer). Proteins were
estimated by Bradford method using BSA as standard.
Results and discussion
In thirty weeks all the animals' injected with azoxymeth-
ane developed at least two tumors in colon with a maxi-
mum of four in two cases. Control rats appeared healthy
without any colon tumors. These tumors ranged from
adenomas (polyp) to highly invasive tumors.
N-Myrsitoyltransferase Activity and Expression in 
Peripheral Blood Mononuclear Cells and Bone Marrow
We have established NMT as a putative therapeutic target
for colon cancer [7]. To examine that NMT, if at all present
in the peripheral blood, can be used as a diagnostic
marker for colon cancer, we investigated the expression
and activity profile in the peripheral blood of normal or
tumor bearing host. NMT activity in the PBMC of tumor
bearing rats (n = 20) was higher compared to PBMC of
control rats (n = 10). NMT activity was approximately
three fold higher in PBMC of tumor bearing rats (Fig. 1).
The highest NMT activity, almost 10 fold greater than
PBMC of control rats, was observed in the PBMC of two
tumor bearing rats with highly invasive tumors. Increased
NMT activity in the PBMC may serve as a diagnostic tool
for colon cancer. NMT activity was almost five folds
higher in bone marrow of tumor bearing rats compared to
normal bone marrow (Fig. 1). Highest activity was
observed in the bone marrow macrophages of tumor
bearing rats. Western analysis was performed to investi-
gate whether higher activity of NMT in PBMC and BM of
NMT activity in peripheral blood mononuclear cells (PBMC)  and Bone Marrow Cells (BMC) of normal and colorectal  tumor bearing rats a; Isolated peripheral blood mononuclear  cells from peripheral blood of control or tumor bearing rat  were assessed for NMT activity Figure 1
NMT activity in peripheral blood mononuclear cells (PBMC) 
and Bone Marrow Cells (BMC) of normal and colorectal 
tumor bearing rats a; Isolated peripheral blood mononuclear 
cells from peripheral blood of control or tumor bearing rat 
were assessed for NMT activity. NMT activity was assayed 
using cAMP-dependent protein kinase derived peptide sub-
strate. Values are mean ± SD of three independent experi-
ments. Inset: Western blot analysis of peripheral blood 
mononuclear cells and bone marrow cells of normal and 
colorectal tumor bearing rats. Proteins (25 μg) from PBMC 
or BMC of control or tumor bearing rats were subjected to 
10% SDS-PAGE, transblotted onto nitrocellulose membrane 
and were probed with monoclonal anti-human NMT anti-
body (1:250 dilutions).Journal of Translational Medicine 2007, 5:58 http://www.translational-medicine.com/content/5/1/58
Page 4 of 6
(page number not for citation purposes)
tumor bearing rats is due to overexpression of NMT or
other proteins (activators/inhibitors) are regulating the
enzymatic activity. The results revealed that there is over-
expression of NMT in the PBMC and BM of tumor bearing
rats compared to that of control rats (Fig. 1 inset). Since
the activity and expression of NMT in the PBMC is ele-
vated in the colon cancer bearing rats, we further investi-
gated whether the immunohistochemical staining of
peripheral blood smear for NMT can be employed for the
diagnostic purpose. In rat peripheral blood, the majority
of mononuclear cells were CD3+ T-cells with a smaller
number of CD20+ (10–15%) B-cells observed. NMT
expression was moderate-strong in >50% mononuclear
cells in cases with tumors (Fig. 2b) while it was absent or
rare weak positivity in controls (Fig. 2a). Intense NMT
expression was observed in PBMC of rats with highly inva-
sive tumors. This intense positive staining for NMT in
tumor bearing rat tissue indicated its potential use as a
diagnostic marker for colon cancer. Therefore, we further
extended our study to human patient samples. Patient
Immunohistochemical analysis of peripheral blood mononuclear cells (PBMC) of normal and tumor bearing hosts Figure 2
Immunohistochemical analysis of peripheral blood mononuclear cells (PBMC) of normal and tumor bearing hosts. Smears of 
peripheral blood cells were incubated with anti-NMT antibody. Peripheral blood mononuclear cells (mostly lymphocytes) from 
control rats were devoid of NMT staining (a), whereas, intense NMT expression was observed in the peripheral blood mono-
nuclear cells of colorectal tumor bearing rats as evident from strong staining (b, see arrows). c negative staining of lymphocytes 
(see arrow) & d; shows negative staining of monocytes (see arrows) in peripheral blood smear of control e; peripheral blood 
smear of colon cancer patients show positive staining of macrophages (arrows), f; peripheral blood smear of colon cancer 
patients show positive staining of neutrophil (fat arrows), lymphocyte (lean long arrow) and macrophages (arrow).Journal of Translational Medicine 2007, 5:58 http://www.translational-medicine.com/content/5/1/58
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details are provided in Table 1. In peripheral blood, the
majority of the mononuclear cells were CD3 positive T-
cells (75 – 80%) admixed with a smaller number of CD20
positive (< 5%) B-cells. CD68 positivity was present in
about 15% of cells, mostly monocytes. As can be seen in
the Table 1 patient with colon cancer tested positive for
NMT in PBMC. Peripheral blood smears from colon can-
cer patients and healthy controls were stained and probed
against anti-CD3, CD68 anti-CD20 and anti-NMT anti-
bodies. NMT staining in the mononuclear cells (including
lymphocytes and monocytes) and neutrophils in the
peripheral blood smears of the healthy controls ranged
from negative to rare weak positivity (Fig. 2c and 2d). Per-
centage of positive staining for NMT in Control subjects'
PBMC is less than 20%. Strong NMT staining was
observed in monocytes, lymphocytes and neutrophils in
the blood smear of the colon cancer patient (Fig. 2e and
2f). More than 80% cells showed positive for PBMC. In
addition, we performed immunohistochemical analysis
on the bone marrow sections of colon tumor bearing rats
and colon cancer patients. As shown in figure 3b and 3d,
NMT was found to be localized in the nuclei as well as in
the cytoplasm of the bone marrow mononuclear cells of
the tumor bearing rats and colon cancer patients whereas
NMT remained cytoplasmic in the control bone marrow
specimens (Fig. 3a and 3c). These results indicate that
NMT is a potential novel marker for the diagnosis of colon
cancer. However, a follow up study with larger samples
size is warranted for its validation and development of a
blood test for the diagnosis of colon cancer.
Conclusion
The strikingly different NMT expression offers the basis of
a potential adjunct investigative tool for screening or diag-
nosis of patients at risk for or suspected of having colon
cancer. Furthermore, altered localization of NMT in BM of
tumor bearing hosts may serve as an added investigative
tool for the diagnostic purpose. To assess the specificity of
Immunohistochemical analysis of Bone Marrow of normal and tumor bearing hosts Figure 3
Immunohistochemical analysis of Bone Marrow of normal and tumor bearing hosts. a; shows cytoplasmic staining of NMT (see 
arrow) in bone marrow cells from control rats, b; whereas, most of the cells shows nuclear localization of NMT in bone mar-
row cells from tumor bearing rat (see arrow). c; NMT staining is mostly cytoplasmic in bone marrow of control (see arrow). d; 
Intense nuclear (and some cytoplasmic) staining for NMT is observed in the bone marrow of colon cancer patient (see arrow).Publish with BioMed Central    and   every 
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the test we performed immunohistochemical staining of
the peripheral blood from a chronic lymphocytic leuke-
mic (CLL) patient. Interestingly, NMT staining was nega-
tive in the lymphoid cells of the CLL patient (data not
shown). A preclinical trial is underway involving larger
sample size of patients and healthy controls to validate
NMT as blood marker for the diagnosis of colon cancer.
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Table 1: Patient data with NMT positivity for peripheral blood mononuclear cells.
Patient Age Sex Diagnosis Staging (TNM) NMT +ve Cells Intensity
1 74 M Adenocarcinoma of the traverse colon pT3b, pN0, pMx > 80% Strong
2 73 F Adenocarcinoma of the cecum pT3a, pN0, pMx > 80% Moderate
3 74 F Adenocarcinoma of the cecum pT3a, pN0, pMx 30–50% Moderate
4 66 F Adenocarcinoma of the ascending colon pT3, pN0, pM0 30–50% Weak
5 66 M Adenocarcinoma of the ascending colon pT3a, pN0, pMx, pV2 30–50% Moderate
6 88 M Adenocarcinoma of the rectum pT2. pN0, pMx 50–75% Moderate
7 75 M Invasive mucinous adenocarcinoma pT4b, pN2, pMx > 75% Moderate
8 83 M Adenocarcinoma of the rectum pT3c/d, pN2 > 75% Strong
Control
14 5 M < 5% Weak
23 4 F < 5% Negative
32 3 F 10–15% Weak
45 9 M 10–15% Moderate
56 4 M > 80% Moderate*
* This was submitted as a control subject and displayed more than 80% positive cells. Later on it was found that the patient had a history of colon 
cancer.